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Abstract: Acetaldehyde is a highly reactive compound that causes various forms of damage to
DNA, including DNA adducts, single- and/or double-strand breaks (DSBs), point mutations, sister
chromatid exchanges (SCEs), and DNA–DNA cross-links. Among these, DNA adducts such as
N2-ethylidene-2′-deoxyguanosine, N2-ethyl-2′-deoxyguanosine, N2-propano-2′-deoxyguanosine,
and N2-etheno-2′-deoxyguanosine are central to acetaldehyde-mediated DNA damage because
they are associated with the induction of DNA mutations, DNA–DNA cross-links, DSBs, and SCEs.
Acetaldehyde is produced endogenously by alcohol metabolism and is catalyzed by aldehyde
dehydrogenase 2 (ALDH2). Alcohol consumption increases blood and salivary acetaldehyde levels,
especially in individuals with ALDH2 polymorphisms, which are highly associated with the risk
of squamous cell carcinomas in the upper aerodigestive tract. Based on extensive epidemiological
evidence, the International Agency for Research on Cancer defined acetaldehyde associated with
the consumption of alcoholic beverages as a “group 1 carcinogen” (definite carcinogen) for the
esophagus and/or head and neck. In this article, we review recent advances from studies
of acetaldehyde-mediated carcinogenesis in the squamous epithelium, focusing especially on
acetaldehyde-mediated DNA adducts. We also give attention to research on acetaldehyde-mediated
DNA repair pathways such as the Fanconi anemia pathway and refer to our studies on the prevention
of acetaldehyde-mediated DNA damage.
Keywords: acetaldehyde; DNA adduct; esophageal squamous cell carcinoma; head and neck
squamous cell carcinoma; DNA damage; cancer development; DNA repair pathway
1. Acetaldehyde, Acetaldehyde Metabolism, and Risk of Cancers
Acetaldehyde, a low molecular weight organic aldehyde with the formula CH3CHO, is a highly
reactive compound that causes DNA damage [1,2]. It is found in food and drinks such as yogurt, ripe
fruits, cheese, coffee, and alcoholic beverages [3,4], and in tobacco smoke [5]. In addition, acetaldehyde
can be produced by microorganisms such as yeasts and bacteria in the human oral cavity [6–8].
Thus, acetaldehyde can be ingested orally in a variety of ways. In particular, alcoholic beverages
such as Calvados and other spirits contain high quantities of “free” acetaldehyde (e.g., Calvados:
1781 ± 861 µM), and frequent consumption of these beverages is associated with an increased risk of
esophageal squamous cell carcinoma (ESCC) [4,9], although “free” acetaldehyde present in alcoholic
beverages appears to cause only a short time (1–2 min) direct exposure to the organs [10].
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More importantly, acetaldehyde is also generated endogenously by alcohol metabolism. Ingested
alcohol is absorbed from the upper gastrointestinal tract and transported to the liver, where it is mainly
metabolized into acetaldehyde by alcohol dehydrogenase 1B (ADH1B), and then detoxified to acetic
acid by aldehyde dehydrogenase 2 (ALDH2) (Figure 1) [11,12]. Genetic polymorphisms in ADH1B
and/or ALDH2 can result in different enzymatic activities that have a major impact on the risk of
ESCC as well as head and neck squamous cell carcinoma (HNSCC) [13–16].
ADH1B has two alleles, ADH1B*1 (less active ADH1B) and ADH1B*2 (active ADH1B, Arg47His).
Therefore, ADH1B is divided into three genotypes; ADH1B*1/*1, less active slow metabolizing
ADH1B, and ADH1B*1/*2 and ADH1B*2/*2, active ADH1B [17]. Since alcohol metabolism is slow
in individuals homozygous for ADH1B*1/*1, acetaldehyde remains in the body for a long time.
Meta-analysis has shown that individuals with ADH1B*1/*1 have a 2.77- and 2.35-fold increased risk of
ESCC [18] and HNSCC [19], respectively, compared with carriers of the ADH1B*2 allele (ADH1B*1/*2
and ADH1B*2/*2).
ALDH2 has two alleles, ALDH2*1 (active ALDH2) and ALDH2*2 (inactive ALDH2, Glu504Lys).
As ALDH2 is a tetrameric enzyme and ALDH2*2 acts in a dominant negative manner, the phenotypic
loss of ALDH2 activity is found in both heterozygous (ALDH2*1/*2) and homozygous (ALDH2*2/*2)
genotypes [20,21]. Subsequently, ALDH2 genotypes are classified as follows: ALDH2*1/*1, active (100%
activity) ALDH2; ALDH2*1/*2, inactive (<10% activity) ALDH2; and ALDH2*2/*2, inactive (0% activity)
ALDH2 [22]. Carriers of the ALDH2*2 allele (ALDH2*1/*2 and ALDH2*2/*2) account for approximately
40% of East Asian populations [23–25], whereas these genotypes are quite rare in Caucasoid or Negroid
populations [26]. Meta-analysis has shown that individuals with ALDH2*1/*2 have a 7.12- and 1.83-fold
increased risk of ESCC [14] and HNSCC [27], respectively, compared with carriers of ALDH2*1/*1.
Moreover, alcoholics with the ALDH2*1/*2 genotype have a 13.5- and 18.52-fold increased risk of ESCC
and HNSCC, respectively, compared with ALDH2*1/*1 genotypes [15].
Thus, extensive epidemiological evidence suggests that acetaldehyde is deeply involved in
the carcinogenesis of the squamous epithelium of the esophagus, and head and neck. In addition,
the International Agency for Research on Cancer has defined acetaldehyde associated with the
consumption of alcoholic beverages as a “group 1 carcinogen” (definite carcinogen) for the esophagus
and/or head and neck [28].
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2. Field Cancerization in the Esophagus, and Head and Neck 
In some patients, ESCC occurs synchronously and/or metachronously in conjunction with 
HNSCC (Figure 2A) [12,29]. In such patients, widespread epithelial oncogenic alterations are 
frequently observed in the esophagus and can be visible as multiple Lugol-voiding lesions (LVLs) by 
Lugol chromoendoscopy (Figure 2B) [30,31]. Thus, multiple occurrences of neoplastic changes in the 
upper aerodigestive tract have been explained by the phenomenon of “field cancerization” [32]. We 
reported previously that the ALDH2*2 allele is the strongest contributing factor (OR: 17.6) for the 
development of multiple LVLs [29]. Our recent prospective cohort study also revealed that the 
severity of LVLs is associated with the amount of average alcohol consumption, and individuals with 
multiple LVLs in their esophagus are especially at high risk for metachronous multiple ESCC and 
HNSCC [33]. Thus, alcohol consumption in individuals with the ALDH2*2 allele is proven to be 
associated with the development of field cancerization in the esophagus, and head and neck. 
Figure 1. Ethanol and acetaldehyde metabolism after alcohol ingestion. Ethanol is metabolized to
acetaldehyde by alcohol dehydrogenase 1B (ADH1B), and then acetaldehyde is degraded to acetic acid
by aldehyde dehydrogenase 2 (ALDH2).
2. Field Cancerization in the Esophagus, and Head and Neck
In some patients, ESCC occurs synchronously and/or metachr nously i conjunction with
HNSCC (Figure 2A) [12,29]. In such patients, widespread epithelial oncogenic alterations are frequently
observed in the esophagus and can be visible as multiple Lugol-voiding lesions (LVLs) by Lugol
chromoendoscopy (Figure 2B) [30,31]. Thus, multiple occurrences of neoplastic changes in the upper
aerodigestive tract have been explained by the phenomenon of “field cancerization” [32]. We reported
previously that the ALDH2*2 allele is the strongest contributing factor (OR: 17.6) for the development
of multiple LVLs [29]. Our recent prospective cohort study also revealed that the severity of LVLs
is associated with the amount of average alcohol consumption, and individuals with multiple LVLs
in their esophagus are especially at high risk for metachronous multiple ESCC and HNSCC [33].
Thus, alcohol consumption in individuals with the ALDH2*2 allele is proven to be associated with the
development of field cancerization in the esophagus, and head and neck.
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Figure 2. Lugol chromoendoscopic images. (A): “Field cancerization” in a patient with esophageal
squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) synchronously.
Location of (a) oropharynx, (b) uvula, (c) upper thoracic esophagus, and (d) lower thoracic esophagus.
Lesions are indicated by arrowheads; (B): (a) normal esophageal mucosa, (b) esophageal mucosa with
multiple dysplastic lesions known as multiple Lugol-voiding lesions. Scale bar = 0.5 cm.
3. Blood and Salivary Acetaldehyde Level after Alcohol Intake
Alcohol consumption increases acetaldehyde concentrations in the blood, saliva, and breath [29,
34,35]. In particular, acetaldehyde concentration reaches a very high level in saliva compared with
blood [6]. When ALDH2*1/*1 or ALDH2*1/*2 carriers drink 0.6 g thanol/kg body weight, salivary
acetaldehyde con e trations immedi t ly reac 24 to 53 µM in ALDH2*1/*1 carriers and 37 to 76 µM in
ALDH2*1/*2 carriers, respectively [36]. The reason for the high acetaldehyde concentrations in saliva is
considered to be associated with the formation of acetaldehyde from ethanol via microbial [6] and/or
mucosal ADH [37]. Moreover, secretion from salivary glands lso influences acetaldehyde concentration in
saliva. Indeed, alcohol drinking (0.5 g ethanol/kg body weight) increases acetaldehyd concentrations in
parotid duct saliva on ALDH2*1/*2 carriers, while it does not affect those on ALDH2*1/*1 carriers [38].
Furthermore, breath acetaldehyde is also thought to dissolve into saliva. The acetaldehyde concentrations
in the oral cavity thus prod c d are equivalent to the co centration that can induce DNA damage
in vitro [6,38]. Therefore, alcohol c nsumption in ALDH2*1/*2 carriers could promote the irect contact
of high acetaldehyde-containing saliva to the surface of the oropharynx, hypopharynx, and esophagus
and has the potential to induce DNA damage in the squamous epithelium. Taken together, sustained
high acetaldehyde-containing saliva is considered to play an important role in the carcinogenesis of upper
digestive tract cancers and it could be involved in “field cancerization.”
4. Acetaldehyde Reacts with DNA to Form DNA Adducts
Acetaldehyde reacts directly with the exocyclic amino group of deoxyguanosine (dG) to form DNA
adducts such as N2-ethylidene-2′-deoxyguanosine (N2-ethylidene-dG) [39], N2-ethyl-2′-deoxyguanosine
(N2-Et-dG) [40,41], and α-S- and α-R-methyl-γ-hydroxy-1, N2-propano-2′-deoxyguanosine (CrPdG)
(Figure 3) [39,42].
N2-ethylidene-dG is generated by a single molecule of acetaldehyde and is the most abundant
DNA adduct derived from acetaldehyde [43]. N2-ethylidene-dG is unstable at the nucleoside level
Int. J. Mol. Sci. 2017, 18, 1943 4 of 12
and is therefore difficult to measure [39]. N2-ethylidene-dG can be stabilized by the chemical
reduction of the Schiff base to the stable product, N2-Et-dG. As endogenous N2-Et-dG is extremely low,
the level of N2-Et-dG that is converted from N2-ethylidene-dG by chemical reduction (e.g., NaBH3CN)
indicates the endogenous N2-ethylidene-dG level [44]. Thus, N2-ethylidene-dG is used for analysis
of acetaldehyde-mediated DNA damage [43,45,46] as a biomarker for acetaldehyde-specific DNA
damage [47]. Indeed, alcohol consumption increases oral N2-ethylidene-dG levels [48,49]. Furthermore,
blood N2-ethylidene-dG levels are definitely increased by alcohol consumption [50] and/or tobacco
smoking [51]. Additionally, blood N2-ethylidene-dG levels in alcoholics with the ALDH2*2 allele are
higher than those with the ALDH2*1/*1 allele [46]. Importantly, alcohol consumption increases the
esophageal N2-ethylidene-dG levels in Aldh2-knockout mice to a higher level than that of wild-type
mice [47,52]. This evidence indicates that drinking alcohol definitely increases acetaldehyde exposure
to the esophageal tissues in individuals with the ALDH2*2 allele.
CrPdG is generated by the reaction of two molecules of acetaldehyde with DNA [53] and exists in
a ring-opened or ring-closed form [54,55]. Here, two molecules of acetaldehyde are converted into
crotonaldehyde and then react with DNA to form CrPdG [56]. The levels of CrPdG are also related to
the amount of acetaldehyde produced [57].
An ethenobase adduct, 1,N2-etheno-2′-deoxyguanosine (NεG), is generated in human cells treated
with acetaldehyde [53]. NεG is a product from 2′-deoxyguanosine and α,β-unsaturated aldehydes that
can be formed during lipid peroxidation mediated by acetaldehyde (Figure 3) [53,58]. As acetaldehyde
induces reactive oxygen species (ROS) that leads to lipid peroxidation [59], generation of NεG can be
triggered by acetaldehyde, ROS, or both.
Int. J. Mol. Sci. 2017, 18, 1943  4 of 12 
 
deoxyguanosine (N2-Et-dG) [40,41], and α-S- and α-R-methyl-γ-hydroxy-1, N2-propano-2′-
deoxyguanosine (CrPdG) (Figure 3) [39,42]. 
N2-ethylidene-dG is generated by a single molecule of acetaldehyde an  is the most abun ant 
DNA adduct derived from acetaldehyde [43]. N2-ethylidene-dG is unstable at the nucleoside level 
and is therefore difficult to measure [39]. N2-ethylidene-dG can be stabilized by the chemical 
reduction of the Schiff base to the stable product, N2-Et-dG. As endogenous N2-Et-dG is extremely 
low, the level of N2-Et-dG that is converted from N2-ethylidene-dG by chemical reduction (e.g. 
NaBH3CN) indic tes the endogenous N2-ethylidene-dG level [44]. Thus, N2-ethylidene-dG is used for 
analysis of acetaldehyde-mediated DNA damage [43,45,46] as a biomarker for acetaldehyde-specific 
DNA damage [47]. Indeed, alcohol consumption increases oral N2-ethylidene-dG levels [48,49]. 
Furthermore, blood N2-ethylidene-dG levels are definitely increased by alcohol consumption [50] 
and/or tobacco smoki g [51]. Additionally, blood N2-ethylidene-dG levels in alcoholics wit  the 
ALDH2*2 allele are higher than those with the ALDH2*1/*1 allele [46]. Importantly, alcohol 
consumption increases the esophageal N2-ethylidene-dG levels in Aldh2-knockout mice to a higher 
level than that of wild-type mice [47,52]. This evidence indicates that drinking alcohol definitely 
increases acetaldehyde exposure to the esophageal tissues in individuals with the ALDH2*2 allele. 
CrPdG is ge erated by the reaction f two molecules of acetaldehyde with DNA [53] and exists 
in a ring-opened or ring-closed form [54,55]. Here, two molecules of acetaldehyde are converted into 
crotonaldehyde and then react with DNA to form CrPdG [56]. The levels of CrPdG are also related 
to the amount of acetaldehyde produced [57]. 
An ethenobase adduct, 1,N2-etheno-2′-deoxyguanosine (NεG), is generated in human cells 
tr ate  with acetaldehyde [53]. NεG is a product from 2′-deoxyguanosine and α,β-unsaturated 
aldehydes that can be formed during lipid peroxidation mediated by acetaldehyde (Figure 3) [53,58]. 
As acetaldehyde induces reactive oxygen species (ROS) that leads to lipid peroxidation [59], 
generation of NεG can be triggered by acetaldehyde, ROS, or both. 
 
Figure 3. Formation of acetaldehyde-mediated DNA adducts. A single molecule of acetaldehyde 
reacts with deoxyguanosine (dG) to generate N2-ethylidene-2′-deoxyguanosine (N2-ethylidene-dG), 
which can be reduced to the stable adducts, N2-ethyl-2′-deoxyguanosine (N2-Et-dG). α-S- and α-R-
methyl-γ-hydroxy-1, N2-propano-2′-deoxyguanosine (CrPdG) is derived from dG and two molecules 
of acetaldehyde. N2-etheno-2′-deoxyguanosine (NεG) is formed from dG and α,β-unsaturated 
aldehydes during lipid peroxidation, which is mediated by acetaldehyde or reactive oxygen species 
(ROS). 
Figure 3. Formation of acetaldehyde-mediated D A ad ucts. A sin le molecule of acetal ehyde reacts
with deoxyguanosine (dG) to generate N2-ethylidene-2′-deoxyguanosine (N2 e hylidene-dG), which can be
reduced to the stable adducts, N2-ethyl-2′-deoxyguanosine (N2-Et-dG). α-S- and α-R-methyl-γ-hydroxy-1,
N2-propano-2′-deoxyguanosine (CrPdG) is derived from dG and two molecules of acetaldehyde.
N2-etheno-2′-deoxyguanosine (NεG) is formed from dG and α,β-unsaturated aldehydes during lipid
peroxidation, which is mediated by acetaldehyde or reactive oxygen species (ROS).
5. DNA Adducts Induce Severe DNA Damage
N2-Et-dG blocks DNA synthesis and induces DNA mutations [60–63]. Moreover, N2-Et-dG inhibits
translesion DNA synthesis (TLS), which leads to a majority of frameshift deletions and a minority of
G:C > T:A transversions in human cells [62]. N2-Et-dG can rotate around the exocyclic nitrogen and the
alpha carbon of acetaldehyde because it has a single bond, whereas N2-ethylidene-dG has a double bond,
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which makes it more hydrophobic than N2-Et-dG. These differences may result in significantly different
mutagenic potential between N2-Et-dG and N2-ethylidene-dG [2].
CrPdG induces DNA interstrand [64] and intrastrand cross-links [65]. The ring-opened form of
CrPdG can react with dG on the opposite strand of the DNA to form DNA interstrand cross-links [66].
A similar mechanism has been suggested for the formation of DNA intrastrand cross-links [2]. Whereas
the ring-closed form of CrPdG would prevent Watson–Crick base pairing with cytosine in the anti
conformation, Hoogsteen base pairing with cytosine would be possible in the syn conformation [55].
CrPdG-mediated disruption of the DNA replication process is thought to cause DNA damage [55,67–69].
NεG inhibits a replicative polymerase δ in complex with proliferating cell nuclear antigen
(PCNA) while translesion polymerases η, ι, and κ can bypass the lesion with varying mutagenic
consequences [70–72]. In cells, replication of a plasmid containing a site-specific NεG induces base-pair
mutations at the NεG site as well as deletions, rearrangements, double mutants, and base-pair substitutions
near the NεG site [73]. These mutations near the NεG site could be triggered by error-prone processing of
DNA double-strand breaks (DSBs) resulting from a replication fork collapse caused by NεG [2]. Certainly,
acetaldehyde blocks DNA replication and increases the level of phosphorylated histone H2AX (γ-H2AX),
a DSB marker, in cells [74].
Acetaldehyde exposure of human cells increases rates of sister chromatid exchange (SCE) [75].
SCE is thought to result from replication-blocking DNA lesions [76]. Although CrPdGs, NεG,
and interstrand cross-links are shown to inhibit replication, the adducts or cross-links that relate
to the formation of SCEs have not been elucidated.
6. Carcinogenic Effects of Acetaldehyde
To elaborate on details mentioned previously in part, acetaldehyde causes DNA adducts [39–42],
DNA single-strand breaks, DSBs [77], point mutations [69], SCEs [78–80], DNA–DNA cross-links [81],
micronuclei [82], and gross chromosomal aberrations [65,80]. Accumulations of these genetic abnormalities
are considered to proceed cancer development. Exposure of acetaldehyde directly induces mutations,
most frequently G:C > A:T transitions in the TP53 gene [83]. This transition pattern is consistent with
that found in a study of the HPRT reporter gene [69]. In addition, G:C > T:A transversions are the most
frequent miscoding events induced by CrPdG, followed by G:C > C:G and G:C > A:T mutations [67–69].
This spectrum of mutations corresponds with the gene variation pattern observed in ESCC [84,85] and
HNSCC [86]. Furthermore, inhalation of acetaldehyde causes nasal and respiratory squamous cell
carcinoma in rats and hamsters [87,88]. These results indicate that acetaldehyde has direct carcinogenic
effects in animals.
7. Repair Pathways of Acetaldehyde-Mediated DNA Damage
Recent research has revealed that cells coordinate multiple processes, such as the Fanconi anemia
(FA) pathway, nucleotide excision repair (NER), homologous recombination (HR), TLS, base excision
repair (BER), fork protection complex, and ATR-dependent cell cycle checkpoint activation, to prevent
and repair acetaldehyde-mediated DNA damage [89].
The specific repair processes for N2-ethylidene-dG and N2-Et-dG remain unknown. The efforts to
identify the repair mechanism for N2-Et-dG are reported to be unsuccessful [2,90].
The most plausible repair pathway of CrPdG is NER [91]. CrPdG generates interstrand cross-links [64],
which can be repaired by the FA pathway [2]. This pathway is composed of at least 19 genes (FANCA,
B, C, D1, D2, E–G, I, J, L–T) and the deficiency of these genes can cause FA [92]. FANCA, B, C, E–G, L,
and M form a core complex at the site of interstrand cross-links and then promote ubiquitination of
the FANCD2–FANCI complex. This ubiquitination leads to the activation of downstream effector
proteins, FANCD1, O, P, and Q. They promote the nucleolytic processing of interstrand cross-links,
followed by DNA repair via HR [93–97]. Indeed, the FA–BRCA network is activated when cells
are treated with ethanol or aldehyde [98,99]. Cells derived from an FA patient are hypersensitive
to acetaldehyde exposure [99,100]. Cells deficient for FANCG, FANCQ, or HR protein Rad51D
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also show many chromosomal aberrations in response to acetaldehyde, while cells deficient for
BER and nonhomologous end-joining show subtle increases in chromosome aberration [101,102].
In vivo, when mice with disrupted Aldh2 locus (Aldh2+/− or Aldh2−/−) and Fancd2 heterozygosity
(Fancd2+/−) are crossed and then challenged with ethanol exposure, the numbers of double-knockout
offspring (Aldh2−/−, Fancd2−/−) are significantly reduced [103]. Treatment with ethanol in adult
double-knockout mice (Aldh2−/−, Fancd2−/−) results in dramatic reductions of bone marrow cells.
Moreover, these mice develop leukemia, even without ethanol administration [103]. These results
indicate that Fancd2 plays an important role in the protection from acetaldehyde-induced genotoxicity.
Acetaldehyde-mediated DSB is repaired by HR [74]. Acetaldehyde accumulates γ-H2AX,
which colocalizes with foci of the HR protein Rad51 in cells [74]. Moreover, recombination-defective
cells are hypersensitive to acetaldehyde [74].
8. Prevention of Acetaldehyde-Mediated DNA Damage
Acetaldehyde-mediated DNA damage is influenced by ALDH2 expression level [52]. ALDH2
is known to express in various tissues including the liver, kidney, muscle, and heart [104]. Recently,
we found that alcohol consumption in mice promoted ALDH2 protein production in esophageal
epithelium [52]. In vitro experiments revealed that ALDH2 is induced by acetaldehyde exposure in
esophageal keratinocytes. ALDH2 knockdown resulted in an increase of susceptibility to acetaldehyde.
Conversely, ALDH2 overexpression prevented acetaldehyde-mediated DNA damage in esophageal
keratinocytes, although overexpression of mutant ALDH2 (ALDH2*2) offered no protection. Thus,
enhancement of ALDH2 expression level may prevent acetaldehyde-mediated DNA damage.
9. Conclusions
Previous studies have provided substantial evidence that acetaldehyde induces various forms of
DNA damage leading to cancer development (Figure 4). DNA adduct formation might be the key
to acetaldehyde-mediated DNA damage; however, the role of DNA adducts in carcinogenesis has
not been completely elucidated. Further studies are necessary to reveal the complete mechanisms of
acetaldehyde-mediated cancer development.
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Figure 4. Summary of acetaldehyde-mediated DNA damage. Acetaldehyde causes DNA adducts,
DNA single-strand breaks, DNA double-strand breaks (DSBs), point mutations, micronuclei, frameshift
mutations, base-pair mutations, deletions, DNA–DNA interstrand or intrastrand cross-links, rearrangements,
and sister chromatid exchanges (SCEs). DNA adducts are considered to be partly (but deeply) involved in
their formation.
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BER Base excision repair
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